Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 14, 2011; 17(34): 3888-3898
Published online Sep 14, 2011. doi: 10.3748/wjg.v17.i34.3888
Published online Sep 14, 2011. doi: 10.3748/wjg.v17.i34.3888
Authors | n | Study design | Dose | Conclusion |
Lu et al[110] | 17 | Randomized, crossover placebo-controlled (8 wk)1 | 3 mg/od | CTT did not change significantly in IBS patients with melatonin treatment |
Saha et al[109] | 18 | Randomized, placebo-controlled (8 wk)1 | 3 mg/od | Significant symptomatic benefit on bowel symptoms, extracolonic symptoms, and quality of life |
Lu et al[108] | 17 | Randomized, crossover placebo-controlled (8 wk)1 | 3 mg/od | Significant symptomatic benefit on IBS scores, anxiety, well-being, and depression scores |
Song et al[107] | 40 | Randomized, placebo-controlled (2 wk)1 | 3 mg/od | Significantly attenuated abdominal pain and reduced rectal pain |
- Citation: Chen CQ, Fichna J, Bashashati M, Li YY, Storr M. Distribution, function and physiological role of melatonin in the lower gut. World J Gastroenterol 2011; 17(34): 3888-3898
- URL: https://www.wjgnet.com/1007-9327/full/v17/i34/3888.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i34.3888